These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 319936)

  • 21. Alterations in plasma dopamine-beta-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma.
    Wocial B; Januszewicz W; Siedlecki I; Feltynowski T; Debiński W
    Endokrinologie; 1982 Feb; 79(1):131-9. PubMed ID: 7084126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fenfluramine in man: hypophagia associated with diminished serotonin turnover.
    Shoulson I; Chase TN
    Clin Pharmacol Ther; 1975 May; 17(5):616-21. PubMed ID: 1092516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in human plasma catecholamines and dopamine-beta-hydroxylase produced by prostaglandin F2 alpha.
    Mueller RA; Fishburne JI; Brenner WE; Braaksma JT; Staurovsky LG; Hoffer JL; Hendricks CH
    Prostaglandins; 1972 Sep; 2(3):219-26. PubMed ID: 4653736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram.
    Lake CR; Major LF; Ziegler MG; Kopin IJ
    Am J Psychiatry; 1977 Dec; 134(12):1411-4. PubMed ID: 920841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients.
    Lake CR; Ziegler MG; Coleman MD; Kopin IJ
    Clin Pharmacol Ther; 1979 Oct; 26(4):428-32. PubMed ID: 487689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of obesity with fenfluramine (Ponderal)].
    Persson I; Andersen UD; Deckert T
    Ugeskr Laeger; 1973 Sep; 135(36):1932-7. PubMed ID: 4590075
    [No Abstract]   [Full Text] [Related]  

  • 27. Variable levels of plasma catecholamines and dopamine beta-hydroxylase in hemodialysis patients.
    Corder CN; Sharma J; McDonald RH
    Nephron; 1980; 25(6):267-72. PubMed ID: 6993966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The therapeutic effect of Fenfluramine on body weight in overweight patients. A controlled clinical study].
    Haug E; Myklebust R
    Tidsskr Nor Laegeforen; 1973 Dec; 93(35):2545-9. PubMed ID: 4589598
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of new formulation of fenfluramine in the management of the obese, diabetic African.
    Wilton D
    Postgrad Med J; 1975; 51 Suppl 1():138-9. PubMed ID: 1219673
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
    Rickels K; Hesbacher P; Fisher E; Perloff MM; Rosenfeld H
    Psychol Med; 1976 Nov; 6(4):623-30. PubMed ID: 794895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prolonged fenfluramine administration in obese and nonobese mice.
    Carr RH; Ipaktchi M; Thenen SW
    Proc Soc Exp Biol Med; 1977 Jan; 154(1):116-20. PubMed ID: 320596
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic effects of fenfluramine--a double-blind study.
    Petrie JC; Mowat JA; Bewsher PD; Stowers JM
    Postgrad Med J; 1975; 51 Suppl 1():139-44. PubMed ID: 768954
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of exogenous prostaglandin E1 on human plasma norepinephrine level and dopamine-beta-hydrolyxase activity.
    Ogawa K; Ito T; Ban M; Matsuno T; Shiozu H; Tsutiya S; Enomoto K
    Acta Biol Med Ger; 1978; 37(5-6):845-8. PubMed ID: 217212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fenfluramine in the treatment of psoriasis. A preliminary report.
    Russell T; Reuter C
    Practitioner; 1975 Jan; 214(1279):114-7. PubMed ID: 1096109
    [No Abstract]   [Full Text] [Related]  

  • 36. Is it dexfenfluramine or weight loss that reduces blood pressure and noradrenergic activity in obese patients?
    Berlin I; Puech AJ
    Eur J Clin Pharmacol; 1993; 44(6):601, 603. PubMed ID: 8405022
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
    Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G
    Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrolytes and norepinephrine levels in blood of patients with cystic fibrosis.
    Lake CR; Davis PB; Ziegler M; Kopin IJ
    Clin Chim Acta; 1979 Mar; 92(2):141-6. PubMed ID: 487568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on the activity of the sympathetic nervous system in essential hypertension.
    Chobanian AV; Garvras H; Gavras I; Bresnahan M; Sullivan P; Melby JC
    J Human Stress; 1978 Sep; 4(3):22-8. PubMed ID: 690418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma norepinephrine and dopamine-beta-hydroxylase in dystonia.
    Ziegler MG; Lake CR; Eldridge R; Kopin IJ
    Adv Neurol; 1976; 14():307-18. PubMed ID: 941776
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.